Six FDA Oncology Decisions Due in 2026 — ADCs, Cell Therapies, and Checkpoint Inhibitors Face Global Catalyst Calendar
Six or more FDA PDUFA decisions are expected in 2026 covering antibody-drug conjugates, checkpoint inhibitors, and precision molecules — the densest oncology approval calendar in years. AbbVie's EHA 2026 data showed venetoclax plus obinutuzumab delivered a median eight years to next treatment in untreated CLL. A Century Therapeutics iPSC cell therapy for type 1 diabetes, affecting nine million people globally, extends the catalyst window into Q1 2027.
Salvado•
